A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study
Por:
Isla D., Felip E., Garrido P., Insa A., Majem M., Remon J., Trigo J.M., de Castro J.
Publicada:
1 ene 2023
Ahead of Print:
1 sep 2022
Resumen:
Purpose This Delphi panel study assessed the level of consensus between medical oncologists on the clinical management of patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC). Methods A modified two-round Delphi approach was used. A scientific committee comprised of medical oncologists developed an online questionnaire. Delphi panel experts rated their level of agreement with each questionnaire statement on a 9-point Likert scale. The questionnaire included 36 statements from 3 domains (clinical management of early-stage NSCLC: 15 statements; role of adjuvant therapy in early-stage NSCLC: 9 statements; and role of adjuvant therapy in early-stage NSCLC with sensitizing EGFR mutation: 12 statements). Results In round 1, consensus was reached for 24/36 statements (66.7%). Nine statements that did not achieve consensus after the first round were evaluated in round 2, and none of them reached consensus. Overall, 84.4% of the panelists agreed that EGFR mutation testing should be done after surgery. Consensus was not achieved on whether the implementation of EGFR mutation testing in resected early-stage NSCLC could limit the use of adjuvant osimertinib. The panelists recognized the rationale for the use of osimertinib in the adjuvant scenario (88%) and 72% agreed that it may change the treatment paradigm in stage IB-IIIA EGFR-mutated NSCLC. Consensus was not reached on the inconvenience of prolonged duration of osimertinib. Conclusions This Delphi study provides valuable insights into relevant questions in the management of early-stage EGFR-mutated NSCLC. However, specific issues remain unresolved. The expert consensus emphasizes the role of adjuvant treatment with osimertinib in this scenario.
Filiaciones:
Isla D.:
Hosp Univ Lozano Blesa, IIS Aragon, Zaragoza, Spain
Felip E.:
Hosp Valle De Hebron, Barcelona, Spain
Garrido P.:
Hosp Univ Ramon y Cajal, Madrid, Spain
Insa A.:
Hosp Clin Univ Valencia, Valencia, Spain
Majem M.:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Remon J.:
CIOCC HM Nou Delfos, Barcelona, Spain
Trigo J.M.:
HC Marbella Hosp Int, Malaga, Spain
de Castro J.:
Hosp Univ La Paz, IDIPAZ, Madrid, Spain
hybrid, All Open Access, Hybrid Gold
|